Immunomedics wins $7.5 million financing
In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.Morris
In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.
Morris Plains, NJ-based Immunomedics plans to use the proceeds of the stock sale to redeem remaining shares of its outstanding preferred stock. In November, the company made an agreement with HFTP Investment to buy 445 of HFTPs preferred shares in the company. The holder of the firms remaining 150 preferred shares, which Immunomedics declined to name, has also agreed to sell those shares to the firm.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
